Literature DB >> 33429752

Whether cognitive behavioral therapy is effective for Alzheimer's disease: A protocol for systematic review and network meta-analysis.

Wan-Qiang Chen1, Fang-Fang Wu2,3, Hong-Bo Lv4, Wen-Ting Xing1, Qi Liu1, Jun-Ping Liu1, Yong-Gui Ge1, Ya-Qin Lu1.   

Abstract

BACKGROUND: Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by impaired memory and cognitive judgment. It is the leading cause of dementia in the elderly, and its high morbidity and mortality have also brought a significant social burden. So far, there is no method can completely cure Alzheimer's dementia, but there are many non-drug treatments that have been praised by people, especially the cognitive behavioral therapy proposed in recent years. The main purpose of this article is to evaluate the effect of cognitive behavioral therapy on the cognitive function improvement of patients with Alzheimer's dementia.
METHODS: We did a network meta-analysis to identify both direct and indirect evidence in relevant studies. A systematic literature search will be performed in the Cochrane Library, PubMed, and EMBASE from inception to October 2020. We extracted the relevant information from these trials with a predefined data extraction sheet and assessed the risk of bias with the Cochrane risk of bias tool.The outcomes investigated were Mini-Mental State Examination and AD Assessment Scale-Cognitive section scores. We did a pair-wise meta-analysis using the fixed-effects model and then did a random-effects network meta-analysis within a Bayesian framework. The = the Assessment of Multiple Systematic Reviews-2 scale, Preferred Reporting Items for Systematic Reviews and Meta-Analyses scale and Grading of Recommendations Assessment, Development and Evaluation were used to assess the quality and evidence grade of the literature. General characteristics of the eligible randomized controlled trials will be summarized and described. Meanwhile, The ADDIS software will be used to perform the network meta-analysis, and the result figures will be generated by STATA 15.0 software.
RESULTS: Using the draft search strategy of databases and after screening,7 randomized controlled trials met the a priori criteria and were included. This network mate-analysis will be published in a peer-reviewed journal.
CONCLUSION: Our study will provide evidence for cognitive behavioral intervention in AD patients. And provide recommendations and guidelines for the clinic. PROTOCOL REGISTRATION: INPLASY2020110052.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33429752      PMCID: PMC7793449          DOI: 10.1097/MD.0000000000023945

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  28 in total

Review 1.  Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies.

Authors:  J Lau; J P Ioannidis; E M Balk; C Milch; N Terrin; P W Chew; D Salem
Journal:  Ann Emerg Med       Date:  2001-05       Impact factor: 5.721

2.  A European consensus on outcome measures for psychosocial intervention research in dementia care.

Authors:  E Moniz-Cook; M Vernooij-Dassen; R Woods; F Verhey; R Chattat; M De Vugt; G Mountain; M O'Connell; J Harrison; E Vasse; R M Dröes; M Orrell
Journal:  Aging Ment Health       Date:  2008-01       Impact factor: 3.658

3.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.

Authors: 
Journal:  BMJ       Date:  2016-07-21

4.  Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil.

Authors:  Sandra Bond Chapman; Myron F Weiner; Audette Rackley; Linda S Hynan; Jennifer Zientz
Journal:  J Speech Lang Hear Res       Date:  2004-10       Impact factor: 2.297

5.  Assessing quality of life in older adults with cognitive impairment.

Authors:  Rebecca G Logsdon; Laura E Gibbons; Susan M McCurry; Linda Teri
Journal:  Psychosom Med       Date:  2002 May-Jun       Impact factor: 4.312

6.  Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis.

Authors:  C Li; Q Ma; S Chen; J Feng; Y He
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2016-04-30       Impact factor: 1.770

7.  The skills and experience of GRADE methodologists can be assessed with a simple tool.

Authors:  Susan L Norris; Joerg J Meerpohl; Elie A Akl; Holger J Schünemann; Gerald Gartlehner; Yaolong Chen; Craig Whittington
Journal:  J Clin Epidemiol       Date:  2016-07-14       Impact factor: 6.437

8.  Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

Authors:  Rik Vandenberghe; Juha O Rinne; Mercè Boada; Sadao Katayama; Philip Scheltens; Bruno Vellas; Michael Tuchman; Achim Gass; Jochen B Fiebach; Derek Hill; Kasia Lobello; David Li; Tom McRae; Prisca Lucas; Iona Evans; Kevin Booth; Gerald Luscan; Bradley T Wyman; Lisa Hua; Lingfeng Yang; H Robert Brashear; Ronald S Black
Journal:  Alzheimers Res Ther       Date:  2016-05-12       Impact factor: 6.982

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

10.  Psychosocial interventions for Alzheimer's disease cognitive symptoms: a Bayesian network meta-analysis.

Authors:  Yuting Duan; Liming Lu; Juexuan Chen; Chunxiao Wu; Jielin Liang; Yan Zheng; Jinjian Wu; Peijing Rong; Chunzhi Tang
Journal:  BMC Geriatr       Date:  2018-08-07       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.